Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vir Biotechnology, Inc.

http://www.vir.bio

Latest From Vir Biotechnology, Inc.

GSK Antibody Appears Effective In Older COVID-19 Patients

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

Research & Development Research and Development Strategies

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation

After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact

The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.

Research & Development BioPharmaceutical

Coronavirus Notebook: UK To Speed Up Trials Of New Drugs, Expands Use Of Tocilizumab

AstraZeneca and BioNTech are both boosting production of their vaccines in Europe, and the first batches of Comirnaty have arrived in Australia and New Zealand.

United Kingdom Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Humabs BioMed SA
UsernamePublicRestriction

Register